Monaco Asset Management SAM Grows Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Monaco Asset Management SAM raised its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Free Report) by 250.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,149,708 shares of the biopharmaceutical company's stock after acquiring an additional 822,037 shares during the period. Monaco Asset Management SAM owned about 1.00% of Fate Therapeutics worth $908,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FATE. CWM LLC raised its stake in shares of Fate Therapeutics by 899.6% in the first quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 37,290 shares during the period. Graham Capital Management L.P. bought a new stake in Fate Therapeutics in the 4th quarter valued at about $37,000. Brevan Howard Capital Management LP purchased a new stake in Fate Therapeutics during the fourth quarter valued at about $41,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Fate Therapeutics during the fourth quarter worth about $55,000. Finally, ProShare Advisors LLC increased its stake in shares of Fate Therapeutics by 77.9% in the fourth quarter. ProShare Advisors LLC now owns 33,645 shares of the biopharmaceutical company's stock worth $56,000 after purchasing an additional 14,728 shares in the last quarter. Hedge funds and other institutional investors own 97.54% of the company's stock.

Fate Therapeutics Stock Performance

Shares of NASDAQ FATE traded down $0.03 during midday trading on Friday, hitting $1.07. 767,002 shares of the company traded hands, compared to its average volume of 1,315,453. Fate Therapeutics, Inc. has a 12-month low of $0.66 and a 12-month high of $4.66. The firm has a market cap of $122.62 million, a P/E ratio of -0.72 and a beta of 2.24. The stock has a 50-day moving average price of $1.22 and a 200 day moving average price of $1.16.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last posted its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.07. The firm had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.18 million. Fate Therapeutics had a negative return on equity of 47.17% and a negative net margin of 1,318.93%. As a group, equities analysts expect that Fate Therapeutics, Inc. will post -1.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Robert W. Baird reduced their price target on Fate Therapeutics from $5.00 to $4.00 and set a "neutral" rating for the company in a research report on Wednesday, May 14th. Wall Street Zen upgraded shares of Fate Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Needham & Company LLC reaffirmed a "hold" rating on shares of Fate Therapeutics in a research note on Thursday, June 12th. Finally, Barclays dropped their price target on shares of Fate Therapeutics from $10.00 to $2.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Eight analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $3.83.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.